iBio, Inc. - Product Pipeline Review - 2014

Published: Nov, 2014 | Pages: 51 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

iBio, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'iBio, Inc. - Product Pipeline Review - 2014', provides an overview of the iBio, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of iBio, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of iBio, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of iBio, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the iBio, Inc.'s pipeline products

Reasons to buy

- Evaluate iBio, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of iBio, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the iBio, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of iBio, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of iBio, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of iBio, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
iBio, Inc. Snapshot 6
iBio, Inc. Overview 6
Key Information 6
Key Facts 6
iBio, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
iBio, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
iBio, Inc. - Pipeline Products Glance 15
iBio, Inc. - Clinical Stage Pipeline Products 15
Phase I Products/Combination Treatment Modalities 15
iBio, Inc. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
iBio, Inc. - Drug Profiles 18
HAC1 vaccine 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
HAI-05 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
malaria vaccine 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
NaAPR1M-74 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
agalsidase alfa 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
anthrax + plague vaccine 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
anthrax vaccine 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
human papillomavirus vaccine 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
IBIOCFB-03 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Monoclonal Antibody for Respiratory Anthrax 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Monoclonal Antibody to Inhibit Neuraminidase for Influenza 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
palivizumab biosimilar 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
plague vaccine 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Recombinant Protein for Undisclosed Indication 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Recombinant Protein to Replace Alpha-1 Antitrypsin for Alpha- Antitrypsin Deficiency 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
respiratory syncytial virus vaccine 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
rituximab biosimilar 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
trypanosomes vaccine 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
yellow fever vaccine 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
influenza vaccine (H7N9) 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
iBio, Inc. - Pipeline Analysis 39
iBio, Inc. - Pipeline Products by Target 39
iBio, Inc. - Pipeline Products by Route of Administration 40
iBio, Inc. - Pipeline Products by Molecule Type 41
iBio, Inc. - Pipeline Products by Mechanism of Action 42
iBio, Inc. - Recent Pipeline Updates 43
iBio, Inc. - Dormant Projects 48
iBio, Inc. - Locations And Subsidiaries 49
Head Office 49
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51

List of Tables
iBio, Inc., Key Information 6
iBio, Inc., Key Facts 6
iBio, Inc. - Pipeline by Indication, 2014 9
iBio, Inc. - Pipeline by Stage of Development, 2014 10
iBio, Inc. - Monotherapy Products in Pipeline, 2014 11
iBio, Inc. - Combination Treatment Modalities in Pipeline, 2014 12
iBio, Inc. - Partnered Products in Pipeline, 2014 13
iBio, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 14
iBio, Inc. - Phase I, 2014 15
iBio, Inc. - Preclinical, 2014 16
iBio, Inc. - Discovery, 2014 17
iBio, Inc. - Pipeline by Target, 2014 39
iBio, Inc. - Pipeline by Route of Administration, 2014 40
iBio, Inc. - Pipeline by Molecule Type, 2014 41
iBio, Inc. - Pipeline Products by Mechanism of Action, 2014 42
iBio, Inc. - Recent Pipeline Updates, 2014 43
iBio, Inc. - Dormant Developmental Projects,2014 48